Safety of ALK Ragweed Tablet

Phase 1CompletedNCT00330083

ALK-Abelló A/S72 enrolled

Overview

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Allergy

Interventions

ALK Ragweed TabletBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ragweed pollen induced rhinoconjunctivitis * Adults of either sex (18-50 years of age) * Positive skin prick test to ragweed Exclusion Criteria: * Previous treatment with immunotherapy

Locations (1)

Healthcare Discoveries Inc.

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Assessment of safety by recording of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.